国: イスラエル
言語: 英語
ソース: Ministry of Health
RISANKIZUMAB
ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL
L04AC18
CONCENTRATE FOR SOLUTION FOR INFUSION
RISANKIZUMAB 60 MG/ML
I.V
Required
ABBVIE INC., USA
RISANKIZUMAB
Skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.
2023-02-20
يزيرياكس لامعتسإ نع تفقوت اذإ ، ً اقبسم بيبطلا ةراشتسإ نودب يزيرياكس لامعتسإ نع فقوتلا زوجي لا .دوعت نأ نكمي كيدل ضارعلأا نإف ،جلاعلا نع تفقوت اذإ ءاودلا عباط صيخشت بجي !ةمتعلا يف ةيودأ لامعتسإ زوجي لا عض .ءاود اهيف لمعتست ةرم لك يف يئاودلا رادقملا نم دكأتلاو .كلذ رملأا مزل اذإ ةيبطلا تاراظنلا رشتسإ ،ءاودلا اذه لامعتسإ لوح ةيفاضإ ةلئسأ كيدل ترفوت اذإ .يلديصلا وأ بيبطلا ةيبناجلا ضارعلأا .4 ىدل ةيبناج ً اضارعأ ببسي دق يزيرياكس لامعتسإ نإ ،ءاود لكب امك زئاجلا نم .ةيبناجلا ضارعلأا ةمئاق نم شهدنت لا .نيلمعتسملا ضعب .اهنم ً ايأ يناعت لاأ ةريطخ ةيبناج ضارعأ يروف لكشب ةيبط ةدعاسم يقلتل هجوتلا وأ بيبطلا عم ثدحتلا كيلع :لثم ،ريطخ ثولتل ضارعأ كيدل تدج ُ و اذإ يليل ق ّ رعت ،ازنإولفنلإاب ةهيبش ضارعأ ،ةنوخس ● رباع ريغ لاعس ،سفنتلا يف قيض وأ قاهرإب روعشلا ● تلاصيوحب قفارتي ملؤم يدلج حفط وأ ،ملؤمو رمحأ ،نخاس دلج ● .يزيرياكس لامعتسإ ةلصاوم كناكمإب ناك اذإ اميف كبيبط ررقي فوس ةيفاضإ ةيبناج ضارعأ :ةيلاتلا ةيبناجلا ضارعلأا ىدحإ ترهظ اذإ كبيبطل ِ كحإ رهظت ضارعأ( ( very common ( ً ادج ةعئاش ةيبناج ضارعأ :(10 نيب نم 1 لمعتسم نم رثكأ ىدل يف ملأ لثم ضارعأب قفارتت يتلا يولعلا يسفنتلا زاهجلا يف تاثولت ● فنلأا يف ناقتحإو ةرجنحلا 1-10 ىدل رهظت ضارعأ( ( common ( 完全なドキュメントを読む
SKY 360-600 JAN24_SPC_clean Page 1 of 16 1 NAME OF THE MEDICINAL PRODUCT Skyrizi ® 600 mg concentrate for solution for infusion Skyrizi ® 360 mg solution for injection in Pre-filled cartridge 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Skyrizi 600 mg concentrate for solution for infusion Each vial contains 600 mg of risankizumab in 10.0 mL of solution (60mg/mL). Skyrizi 360 mg solution for injection in Pre-filled cartridge Each Pre-filed cartridge contains 360 mg of risankizumab in 2.4 mL solution (150 mg/mL). Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Skyrizi 600 mg concentrate for solution for infusion (infusion) The solution is colourless to slightly yellow and clear to slightly opalescent Skyrizi 360 mg solution for injection (injection) The solution is colourless to yellow and clear to slightly opalescent. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Risankizumab is indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable. 4.2 Posology and method of administration Skyrizi is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Skyrizi is indicated. Posology SKY 360-600 JAN24_SPC_clean Page 2 of 16 The recommended dose is 600 mg administered by intravenous infusion at Week 0, Week 4, and Week 8, followed by 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Missed dose If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time. Special populations Elderly (aged 65 years and ove 完全なドキュメントを読む